Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trialJong Wook Lee, Yasuo Mori, Jin Seok Kim et al.|The Lancet Haematology|2023Cited by 88
Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapyEfstathios Kastritis, Meletios Α. Dimopoulos, Maria Gavriatopoulou et al.|American Journal of Hematology|2017Cited by 73
Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosisEfstathios Kastritis, Meletios Α. Dimopoulos, Ioannis Papassotiriou et al.|Blood|2016Cited by 50
Effect of cA2 Anti–Tumor Necrosis Factor-α Antibody Therapy on Hematopoiesis of Patients with Myelodysplastic SyndromesAnna Boula, Helen Α. Papadaki, Michael Voulgarelis et al.|Clinical Cancer Research|2006Cited by 27